# US 2020/0368159 A1 · Aqueous formulation for insoluble drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368159 A1
- Document ID: US20200368159A1
- Status: Published application
- Kind: A1
- Application number: 16/993,017
- Filed: 2020-08-13
- Published: 2020-11-26
- Earliest claimed: 2018-03-07
- Assignees: Andrew Xian Chen
- Inventors: Andrew Xian CHEN; Jan-Jon CHU; Jianmin XU; Mohammad Saiful ISLAM
- Web page: https://patentgrep.com/patent/US20200368159A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/415: 1,2-Diazoles
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/18: Iodine; Compounds thereof
- A61K 38/13: Cyclosporins
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to clear one-phase liquid formulation vehicles comprising lecithin, MCT, bile salt and water.

## Claims

### Claim 1

An injectable solubilizer composition, comprising:
a. a lecithin, having phosphatidylcholine content no less than 75% w/w based on the lecithin weight;
b. a medium chain triglyceride (MCT) having fatty acids of chain length of about 6 to 12 carbons;
c. a bile salt; and
d. water, where the said composition is a clear and one-phase aqueous solution.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein:
a. lecithin is at a concentration between about 6% and about 72.5%;
b. medium chain triglycerides (MCT) is at a concentration between 0% and about 32.5%;
c. bile salt is at a concentration between about 11.5% and about 94%; and
d. water, where the % is the weight percentage over the total weight of lecithin, MCT and bile salt.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the lecithin, MCT and bile salt concentrations are within a zone in a ternary phase diagram (FIG. 1) having lecithin, MCT and bile salt as the three components, wherein the zone is enclosed by the following compositions:
Compositions
Concentration (% w/w based on the total
(Border points
weight of lecithin, MCT and bile salt)
as in FIG. 1)
Lecithin
MCT
Bile salt
A
72.5
0
27.5
B
61
27
12
C
56
32.5
11.5
D
52
32.5
15.5
E
50
10
40
F
6
0
94

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the water concentration is no less than about 0.1/1 in weight ratio of water to the total weight of lecithin, MCT and bile salt.

### Claim 5 (depends on 1)

The composition according to claim 1, where the composition is substantially free of liposome, emulsion, phospholipid particles or oil droplets of size greater than 5 nanometers in diameter.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the lecithin is derived from a natural source or is synthetically made.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the MCT is derived from a natural source or is synthetically made.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the bile salt is selected from a group consisting of sodium, potassium, lithium, calcium, arginine, lysine or ammonium salts of cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid, glyco- or taurodeoxycholic acid, chenodeoxycholic acid, glyco- or taurochenoxydeoxycholic acid, or a mixture thereof.

### Claim 9 (depends on 1)

The composition according to claim 1, that further contains an alcohol selected from a group consisting of ethanol, benzyl alcohol, propylene glycol, polyethylene glycol of a low molecular weight (100-5,000) or a combination thereof.

### Claim 10 (depends on 9)

The composition according to claim 9, wherein the alcohol concentration is no more than about 1.6/1 in weight ratio of alcohol to the total weight of lecithin, MCT and bile salt.

### Claim 11 (depends on 1)

The composition according to claim 1, that the composition is a Universal Solubilizer.

### Claim 12 (depends on 1)

The composition according to claim 1, that the composition is an amorphous solid.

### Claim 13 (depends on 1)

The composition according to claim 1, further contains an insoluble or soluble drug.

### Claim 14 (depends on 13)

The composition according to claim 13, wherein the drug is selected from a group consisting of small molecules, peptides, proteins or a combination thereof.

### Claim 15 (depends on 13)

The composition according to claim 13, that contains one or more insoluble drug(s) selected from a group consisting of amiodarone, amphotericin, aprepitant, camptothecin, cannabidiol, casein, celecoxib, clarithromycin, cyclosporine, diazepam, docetaxel, ibuprofen, iodine, itraconazole, iodine, irinotecan, levodopa, paclitaxel, phytonadione, posaconazole, prednisolone acetate, progesterone, propofol, resveratrol, tetrahydrocannabinol, tyrosine, voriconazole, PGE2, PGE1, opalmon, piroxicam, benexate, dexamethasone, nitroglycerin, cefotiam-hexetil, cephalosporin, tiaprofenic acid, diphenhydramin and chlortheophyllin, chlordiazepoxide, hydrocortisone, cisapride, nimesulide, alprostadil, nicotine, chloramphenicol, diclofenac sodium, estradiol, indomethacin, omeprazol, ziprasidone, dextromethorphan, cetirzine, mitomycin, meloxicam, aripiprazole or salt thereof.

### Claim 16 (depends on 1)

The composition according to claim 1, comprising voriconazole at a concentration between 0.01% and about 3%, lecithin at a concentration between about 6% and about 72.5%, MCT at a concentration between 0 and about 32.5%, glycocholic acid at a concentration between about 11.5% and about 94%, wherein the % is the weight percentage over the total weight of lecithin, MCT and glycocholic acid, and pH of the solution is between 3.5 and 7.5.

### Claim 17 (depends on 1)

The composition according to claim 1, comprising diazepam at a concentration between 0.01% and about 3%, lecithin at a concentration between about 6% and about 72.5%, MCT at a concentration between 0 and about 32.5%, glycocholic acid at a concentration between about 11.5% and about 94%, wherein the % is the weight percentage over the total weight of lecithin, MCT and glycocholic acid, and pH of the solution is between 6 and 8.5.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the composition has at least one of the following pharmacokinetic parameters following a subcutaneous injection of a 10 mg diazepam dose into humans:
(a) AUC(0-t) is about 6194 ng×h/mL
(b) AUC(0-inf) is about 6688 ng×h/mL, and
(c) Cmax is about ng/mL

### Claim 19 (depends on 1)

The composition according to claim 1, wherein the pH of the composition is between 3 and 10.

### Claim 20 (depends on 1)

The composition according to claim 1, that further contains:
a) a preservative selected from a group consisting of cresols, phenol, benzyl alcohol, ethanol, chlorobutanol, parabens, imidura, benzylkonium chloride, EDTA or a salt or a combination thereof; or
b) a bulking agent selected from a group consisting of mannitol, sorbitol, xylitol, lactose, fructose, xylose, sucrose, trehalose, mannose, maltose, dextrose, dextran, dextrin, or a combination thereof; or
c) an antioxidant selected from: EDTA, citric acid, glycine, butylated hydroxyanisole, butylated hydroxytoluene, cysteine, methionine, thioglycerol, bisulfite, metabisulfate, ascorbate, propyl gallate, tocopherol, reducing sugar, or a salt or combination thereof.

### Claim 21 (depends on 1)

The composition according to claim 1, wherein said composition is administered to a human or animal subject by oral administration, injection through a needle, instillation through a catheter, or applications onto the skin, mucous membranes, in wounds, into the eyes, ears, vagina, urethra or rectum.

### Claim 22 (depends on 16)

The composition according to claim 16, wherein said composition has a light transmittance (T800) of no less than 80%; or wherein said composition has a viscosity in a range between about 10 and 1000 cP.

### Claim 23 (depends on 1)

A method for preparation of a composition according to claim 1, comprising (a) dissolving a lecithin to a concentration between about 6% and about 72.5%, a medium chain triglyceride (MCT) to a concentration between 0% and about 32.5% and a bile salt to a concentration between about 11.5% and about 94%, all in weight percent over the total weight of lecithin, MCT and bile salt, in water to a concentration no less than about 0.1/1 (w/w) in water to the total weight of lecithin, MCT and bile salt ratio, to form a clear one-phase aqueous solution composition, and (b) adjusting pH to between 3 and 10.
